RE: Lilly ...FT Today4 Oct 2023 09:09
The broad patent family that Avacta has licensed from Bach until patent expiry (from early 2030s to early 2040s), provides globally exclusive usage of the substrate in therapeutic agents (small molecules, biologics, ADCs, etc). During that time, each individual drug that has been modified with the pre|CISION substrate, can then be patented by Avacta, for at least a further 20 years.